-
Next generation screening – Could genetics hold the key?
-
Darolutamide (Nubeqa) – Hope for men with high-risk non-metastatic hormone resistant prostate cancer
-
Online Community counts down to launch of new technology platform
-
Prostate Cancer Foundation of Australia launches emergency telenursing appeal
-
Advancing precision medicine for metastatic prostate cancer - US FDA approves new PARP inhibitors
-
Community luminaries win prestigious prostate cancer award